Royalty Pharma plc (RPRX) FY2024 Q3 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2024-09-30

Swipe to see the full flow
Royalty Pharma plc (RPRX) FY2024 Q3 Balance SheetBalance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.Current liabilities$1.17 BCurrent assets$1.79 BLiabilities$7.78 BAssets$18.04 BNon-current liabilities$6.62 BNon-current assets$16.25 BEquity$10.26 BGross equity(calculated)$10.26 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsFinancial royalty assetsAvailable for sale debt securitiesOther royalty income receivableOther current assetsFinancial royalty assets, netAvailable for sale debt securitiesEquity method investmentsEquity securitiesOther assetsCurrent portion of long-term debtDistributions payable to legacy non-controlling interestsInterest payableOther current liabilitiesAccounts payable and accrued expensesLong-term debtOther liabilitiesAdditional paid-in capitalRetained earningsCommon stock - Class R Redeemable SharesCommon stock - Class A Ordinary SharesNon-controlling interestsCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury interestsCurrent portion of long-term debtCurrent portion of long-term debt$996.94 MCash and cash equivalentsCash and cash equivalents$950.05 MDistributions payable to legacy non-controlling interestsDistributions payable to legacynon-controlling interests$79.15 MCurrent liabilitiesCurrent liabilities$1.17 BFinancial royalty assetsFinancial royalty assets$765.77 MCurrent assetsCurrent assets$1.79 BInterest payableInterest payable$38.41 MAvailable for sale debt securitiesAvailable for sale debt securities$48.50 MLiabilitiesLiabilities$7.78 BOther current liabilitiesOther current liabilities$31.20 MOther royalty income receivableOther royalty income receivable$24.90 MAssetsAssets$18.04 BAccounts payable and accrued expensesAccounts payable and accrued expenses$22.06 MOther current assetsOther current assets$4.97 MNon-current liabilitiesNon-current liabilities$6.62 BNon-current assetsNon-current assets$16.25 BLong-term debtLong-term debt$6.61 BEquityEquity$10.26 BFinancial royalty assets, netFinancial royalty assets, net$14.97 BOther liabilitiesOther liabilities$5.58 MGross equity (calculated)Gross equity(calculated)$10.26 BAdditional paid-in capitalAdditional paid-in capital$4.11 BRetained earningsRetained earnings$2.76 BAvailable for sale debt securitiesAvailable for sale debt securities$657.30 MCommon stock - Class R Redeemable SharesCommon stock - Class R Redeemable Shares$63.00 KEquity method investmentsEquity method investments$351.02 MCommon stock - Class A Ordinary SharesCommon stock - Class A Ordinary Shares$45.00 KEquity securitiesEquity securities$228.87 MNon-controlling interestsNon-controlling interests$3.39 BOther assetsOther assets$42.79 MTreasury interestsTreasury interests−$2.66 M
Chart details

Royalty Pharma plc (RPRX) FY2024 Q3 Balance Sheet

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

Assets
18,042,242,000 US dollars
Current assets
1,794,195,000 US dollars
Non-current assets
16,248,047,000 US dollars
Liabilities
7,783,775,000 US dollars
Current liabilities
1,167,758,000 US dollars
Non-current liabilities
6,616,017,000 US dollars
Equity
10,258,467,000 US dollars
Noncontrolling interest
3,388,589,000 US dollars. Included in consolidated equity; this amount is not added again.
Cash and cash equivalents
950,052,000 US dollars
Financial royalty assets
765,773,000 US dollars
Available for sale debt securities
48,500,000 US dollars
Other royalty income receivable
24,901,000 US dollars
Other current assets
4,969,000 US dollars
Financial royalty assets, net
14,968,074,000 US dollars
Available for sale debt securities
657,300,000 US dollars
Equity method investments
351,017,000 US dollars
Equity securities
228,867,000 US dollars
Other assets
42,789,000 US dollars
Current portion of long-term debt
996,942,000 US dollars
Distributions payable to legacy non-controlling interests
79,149,000 US dollars
Interest payable
38,412,000 US dollars
Other current liabilities
31,200,000 US dollars
Accounts payable and accrued expenses
22,055,000 US dollars
Long-term debt
6,610,437,000 US dollars
Other liabilities
5,580,000 US dollars
Additional paid-in capital
4,107,742,000 US dollars
Retained earnings
2,764,685,000 US dollars
Common stock - Class R Redeemable Shares
63,000 US dollars
Common stock - Class A Ordinary Shares
45,000 US dollars
Common stock - Class B Ordinary Shares
0 US dollars
Deferred shares, $0.000001 par value; issued and outstanding: 2024–390,502 and 2023–384,640
0 US dollars
Non-controlling interests
3,388,589,000 US dollars
Treasury interests
negative 2,657,000 US dollars
Gross equity (calculated)
10,261,124,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Royalty Pharma plc (RPRX) FY2024 Q3 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!